Identification of a New Ovarian Cancer Gene
Inherited mutations are believed to be the cause behind more than 10% of ovarian cancers. Work carried out over the past two decades has identified a number of genes that, when mutated, lead to a significantly higher risk of developing the disease as compared to the general population – two such well known genes are Read More
Degradomics is a new field in the OMICS world – A report from the FRIAS conference about Integrative OMICS in Freiburg, Gemany
At this interdisciplinary omics conference results and impact of the omics fields were discussed, including the emergence of a new field, degradomics, which focuses on the identification of cleavage sites. The omics research opens great opportunities for the discovery of new biomarkers for early diagnosis of diseases and identification of new drug targets. In the Read More
Data sharing in the life sciences – Part II
In part I of our series on data sharing, reproduced with permission from Frank Schacherer’s blog, we considered the question of “Who should have access to data? ” and left off with the question of “Who pays for the data?”. Frank writes: “Following the reasoning that biomedical data is a common good, a kind of Read More
BioKnowledge Transfer goes high-throughput, and other product news from BIOBASE
Each quarter we provide a newsletter for our subscribers covering relevant industry updates, new product release information, and other news on our products. In our just released Fall 2011 Newsletter we discussed recent advancements in our BioKnowledge Transfer (BKT) process – which is our method for providing clues to the function of proteins not yet Read More
Data sharing in the life sciences – Part I
What is the best way to create, share and maintain biological databases? This is a question our COO, Frank Schacherer, has blogged about on his own website. Over a series of posts, we’ll reproduce his thoughts here with permission. Frank writes: “If nature has made any one thing less susceptible than all others of exclusive Read More
Beyond Next Generation Sequencing – A report from the BNGS workshop at the Renyi Institute in Hungary
NGS technologies have revolutionized the speed and detail with which scientists acquire genomic and transcriptomic information, while requiring only a fraction of the cost of classical sequencing strategies – opening up novel research possibilities in many areas including cancer research, gene regulation, epigenetics, personalized medicine and pharmacogenomics. As many of us know, such advancements in Read More
G over C Mutation Bias in Human Genetic Disease Helps in Clinical Scoring of Causative Mutations
When double or multiple de novo point mutations are encountered in a molecular diagnostic screen for a monogenic disease, are there any quick techniques for identifying which is more likely to be the causative mutation? According to a recent study published by Xiao et al, the answer is yes – if the point mutations involve Read More
Is your next generation sequencing deep enough?
With so many of our researchers being passionate about understanding the role of transcription factors in any number of normal or disease processes, combined with the opportunity that next generation sequencing (NGS) technology has brought to understanding these processes at a genomic level, you can imagine why a recent Nature Scientific Report caught the eye Read More
Webinar: Strategies for Transcription Factor Binding Site Prediction
Wednesday, September 28, 2011
5:00 PM Central European / 11:00 AM EST (Eastern Standard – US) / 8:00 AM PC (Pacific Standard – US)